Total Payments
$13,025
2024 Payments
$4,913
Companies
74
Transactions
456
Medicare Patients
2,314
Medicare Billing
$594,801
Payment Breakdown by Category
Food & Beverage$10,045 (77.1%)
Travel$2,142 (16.4%)
Consulting$400.00 (3.1%)
Education$384.91 (3.0%)
Gifts$53.20 (0.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,045 | 441 | 77.1% |
| Travel and Lodging | $2,142 | 6 | 16.4% |
| Consulting Fee | $400.00 | 1 | 3.1% |
| Education | $384.91 | 6 | 3.0% |
| Gift | $53.20 | 2 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| US Oncology Corporate, Inc. | $3,750 | 11 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $838.52 | 21 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $726.32 | 44 | $0 (2024) |
| Genentech USA, Inc. | $594.49 | 38 | $0 (2024) |
| Amgen Inc. | $481.37 | 30 | $0 (2024) |
| Eisai Inc. | $390.79 | 19 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $357.63 | 27 | $0 (2024) |
| SOBI, INC | $356.67 | 15 | $0 (2024) |
| Janssen Biotech, Inc. | $353.53 | 19 | $0 (2024) |
| Merck Sharp & Dohme LLC | $300.44 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,913 | 149 | US Oncology Corporate, Inc. ($1,096) |
| 2023 | $3,267 | 95 | US Oncology Corporate, Inc. ($1,295) |
| 2022 | $2,478 | 54 | US Oncology Corporate, Inc. ($1,359) |
| 2021 | $323.90 | 16 | Novartis Pharmaceuticals Corporation ($64.41) |
| 2020 | $26.55 | 2 | Integra LifeSciences Corporation ($15.28) |
| 2019 | $59.56 | 4 | Janssen Biotech, Inc. ($27.35) |
| 2018 | $1,254 | 85 | Novartis Pharmaceuticals Corporation ($261.33) |
| 2017 | $703.56 | 51 | Genentech USA, Inc. ($219.05) |
All Payment Transactions
456 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $30.20 | General |
| Category: Genetically Defined Disease | ||||||
| 12/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $26.95 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $26.18 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $23.90 | General |
| Category: Oncology | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $15.34 | General |
| Category: Oncology | ||||||
| 12/16/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $31.98 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $27.93 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $17.29 | General |
| Category: Oncology | ||||||
| 12/05/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $21.82 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $29.40 | General |
| 11/27/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $24.77 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/26/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $22.51 | General |
| 11/25/2024 | PFIZER INC. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $26.66 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Genentech USA, Inc. | Itovebi (Biological), Phesgo | Food and Beverage | In-kind items and services | $27.24 | General |
| Category: BioOncology | ||||||
| 11/14/2024 | Octapharma USA, Inc. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) | Food and Beverage | In-kind items and services | $25.29 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $18.53 | General |
| 11/12/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $33.38 | General |
| Category: Rare Disease | ||||||
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $22.42 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $21.01 | General |
| Category: Hematology/Oncology | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $32.54 | General |
| 11/05/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: ONC | ||||||
| 11/04/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $19.92 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $21.41 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 596 | 2,975 | $496,764 | $146,511 |
| 2022 | 20 | 791 | 3,099 | $624,027 | $192,077 |
| 2021 | 8 | 577 | 1,702 | $448,331 | $167,432 |
| 2020 | 7 | 350 | 927 | $149,903 | $88,781 |
Total Patients
2,314
Total Services
8,703
Medicare Billing
$594,801
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 120 | 418 | $111,188 | $40,217 | 36.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 123 | 364 | $121,940 | $35,341 | 29.0% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 12 | 1,600 | $104,000 | $25,906 | 24.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 130 | 160 | $82,560 | $22,318 | 27.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 39 | 112 | $20,720 | $7,187 | 34.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 30 | 40 | $18,760 | $5,646 | 30.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 42 | 42 | $18,354 | $5,267 | 28.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 14 | 17 | $4,641 | $1,579 | 34.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 21 | 128 | $4,608 | $1,376 | 29.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 13 | 17 | $3,162 | $797.57 | 25.2% |
| G0316 | Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | Facility | 2023 | 12 | 25 | $6,250 | $614.25 | 9.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 12 | 19 | $152.00 | $148.96 | 98.0% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 11 | 11 | $385.00 | $102.10 | 26.5% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 17 | 22 | $44.00 | $11.19 | 25.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 142 | 682 | $181,412 | $56,762 | 31.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 187 | 247 | $127,194 | $39,420 | 31.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 115 | 350 | $117,250 | $35,266 | 30.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 91 | 407 | $75,626 | $23,573 | 31.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 16 | 106 | $39,750 | $11,444 | 28.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 21 | 40 | $18,760 | $5,844 | 31.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 24 | 24 | $13,848 | $4,394 | 31.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 28 | 28 | $12,236 | $3,802 | 31.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 13 | 95 | $7,695 | $2,315 | 30.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 18 | 25 | $6,825 | $2,122 | 31.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 20 | 22 | $5,192 | $1,574 | 30.3% |
About Dr. Mohammad Mobayed, MD
Dr. Mohammad Mobayed, MD is a Hematology & Oncology healthcare provider based in Rochester Hills, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2007. The National Provider Identifier (NPI) number assigned to this provider is 1114134632.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mohammad Mobayed, MD has received a total of $13,025 in payments from pharmaceutical and medical device companies, with $4,913 received in 2024. These payments were reported across 456 transactions from 74 companies. The most common payment nature is "Food and Beverage" ($10,045).
As a Medicare-enrolled provider, Mobayed has provided services to 2,314 Medicare beneficiaries, totaling 8,703 services with total Medicare billing of $594,801. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Rochester Hills, MI
- Active Since 05/16/2007
- Last Updated 05/26/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1114134632
Products in Payments
- IMFINZI (Biological) $479.38
- Lenvima (Drug) $390.79
- KISQALI (Drug) $341.67
- KEYTRUDA (Biological) $300.44
- Doptelet (Drug) $243.26
- SARCLISA (Biological) $186.74
- OPDIVO (Biological) $183.49
- XPOVIO (Drug) $183.02
- VERZENIO (Drug) $177.15
- IMBRUVICA (Drug) $155.01
- FOTIVDA (Drug) $143.90
- Neulasta (Biological) $139.18
- PADCEV (Biological) $128.76
- IBRANCE (Drug) $127.63
- Enhertu (Drug) $127.44
- PROMACTA (Drug) $122.19
- Alecensa (Biological) $122.03
- JAKAFI (Drug) $120.70
- Nplate (Biological) $119.14
- DOPTELET (Drug) $113.41
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.